Literature DB >> 8842789

Restenosis is associated with decreased coronary artery nitric oxide synthase.

P R Myers1, R Webel, V Thondapu, X P Xu, J Amann, M A Tanner, J S Jenkins, J S Pollock, M H Laughlin.   

Abstract

The purpose of the present study was to test the hypothesis that restenosis is associated with decreased constitutive nitric oxide synthase activity. Male miniswine with moderately elevated serum cholesterol levels underwent cardiac catheterization and oversized balloon injury to the right and left circumflex coronary arteries, followed 2 weeks later by repeat injury on the same coronary segments. After 4 weeks, the coronary arteries were either immediately frozen in liquid nitrogen or pressure-perfusion fixed and prepared for histologic examination. Constitutive nitric oxide synthase activity was quantified using a fibroblast reporter cell method, while constitutive nitric oxide synthase protein was compared between balloon-injured and non-balloon-injured arteries using Western blot analysis. Immunohistochemical studies were performed using a specific antibody against constitutive nitric oxide synthase protein. Following balloon injury, there was decreased constitutive nitric oxide synthase activity in balloon-injured coronary arteries, compared to distal non-balloon-injured segments from the same artery. Histological examination demonstrated an intact endothelium. Specific antibody staining revealed that there was less constitutive nitric oxide synthase protein reactivity by immunohistochemical analysis. Western analysis confirmed less constitutive nitric oxide synthase protein. The data are consistent with the hypothesis that restenosis is associated with decreased endothelial cell nitric oxide production. The data suggest this is secondary to a decreased amount of constitutive nitric oxide synthase enzyme in the endothelium. A deficiency in constitutive nitric oxide synthase enzyme may contribute to the impaired second messenger and paracrine functions of the endothelium observed during restenosis following balloon injury, including abnormal vasomotion, extracellular matrix formation, and platelet aggregation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8842789     DOI: 10.1016/0167-5273(96)02684-8

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

1.  Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis.

Authors:  Claudio Napoli; Giancarlo Aldini; John L Wallace; Filomena de Nigris; Roberto Maffei; Pasquale Abete; Domenico Bonaduce; Gianluigi Condorelli; Franco Rengo; Vincenzo Sica; Francesco P D'Armiento; Chiara Mignogna; Gaetano de Rosa; Mario Condorelli; Lilach O Lerman; Louis J Ignarro
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-29       Impact factor: 11.205

Review 2.  Restenosis after PCI. Part 1: pathophysiology and risk factors.

Authors:  J Wouter Jukema; Jeffrey J W Verschuren; Tarek A N Ahmed; Paul H A Quax
Journal:  Nat Rev Cardiol       Date:  2011-09-13       Impact factor: 32.419

3.  Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice.

Authors:  C Napoli; G Cirino; P Del Soldato; R Sorrentino; V Sica; M Condorelli; A Pinto; L J Ignarro
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

4.  Time dependent changes of arterial distensibility induced by cholesterol and balloon injury in rabbits: an in vivo intravascular ultrasound study.

Authors:  Michael Ribbing; Anja Dorszewski; Holger Reinecke; Günter Breithardt; Sebastian Kerber
Journal:  Int J Cardiovasc Imaging       Date:  2002-12       Impact factor: 2.357

5.  Stabilizing Peri-Stent Restenosis Using a Novel Therapeutic Carrier.

Authors:  Patrick H Kee; Melanie R Moody; Shao-Ling Huang; Hyunggun Kim; Xing Yin; Tao Peng; Susan T Laing; Melvin E Klegerman; Mohammad H Rahbar; Deborah Vela; Curtis Genstler; Kevin J Haworth; Christy K Holland; David D McPherson
Journal:  JACC Basic Transl Sci       Date:  2019-11-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.